cropped color_logo_with_background.png

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Study Purpose

This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back (recurrent). Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and interfere with the ability of tumor cells to grow and spread. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histologically proven diagnosis of glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma); patients will be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made.
  • - The tumor must be supratentorial; patients with infratentorial disease, spinal cord disease, and/or leptomeningeal disease are excluded.
  • - Patients must have shown unequivocal evidence for tumor progression on the previous treatment regimen (prior to enrollment on this study) by magnetic resonance imaging (MRI) scan of the brain with and without contrast within 14 days prior to registration; the dose of steroids must be stable or decreasing for at least 5 days prior to the scan; patients with tumor progression who then undergo surgical resection prior to enrollment on study may be eligible as long as pathology confirms progressive or recurrent glioblastoma multiforme (GBM) (or variants); for patients who undergo surgical resection, registration on study may not occur any sooner than 28 days from surgery; an MRI scan of the brain with and without contrast is still required within 14 days prior to registration on study but is not required to demonstrate measurable disease or tumor progression after surgery.
  • - Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided computed tomography (CT) scans are obtained and are of sufficient quality; patients without non-compatible devices may not have CT scans performed to meet this requirement.
  • - History/physical examination within 14 days prior to registration.
  • - Karnofsky performance scale >= 70 within 14 days prior to registration.
  • - Patients who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustine, must have confirmation of progressive disease within 14 days prior to registration based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging, or histopathology.
  • - Leukocytes > 3,000/mm^3 (within 14 days prior to registration) - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 14 days prior to registration) - Hemoglobin >= 10.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dL is acceptable) (within 14 days prior to registration) - Platelets >= 100,000 cells/mm^3 (within 14 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal (within 14 days prior to registration) - Bilirubin =< 2.0 mg/dL (within 14 days prior to registration) - Creatinine within normal upper institutional limits or creatinine clearance > 60 mL/min/1.73 m^2 (per 24 hour urine collection or calculated according to the Cockcroft-Gault formula) for subjects with creatinine levels above the institutional normal (within 14 days prior to registration) - Patients with creatinine levels below normal institutional limits are eligible.
  • - Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 (within 14 days prior to registration) - Urinary protein =< 30 mg/dL in urinalysis or =< 1+ on dipstick (within 14 days prior to registration) - Generally well-controlled blood pressure with systolic blood pressure =< 140 mm Hg AND diastolic blood pressure =< 90 mm Hg within 5 days prior to registration; the use of anti-hypertensive medications to control hypertension is permitted.
  • - Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test within 14 days prior to registration.
  • - Women of childbearing potential and male patients who are sexually active must practice adequate contraception during therapy and for 180 days (6 months) afterwards.
  • - Patient must provide study specific informed consent prior to study entry.

Exclusion Criteria:

  • - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) - Prior systemic cytotoxic chemotherapy within (i.e., =<) 28 days (42 days for nitrosoureas or mitomycin C) prior to registration, or patients who have not returned to baseline or =< Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v.
4) grade 2 from adverse events (excluding alopecia) due to agents administered more than 28 days prior to registration.
  • - Patients who received non-cytotoxic drug therapy must be off treatment for at least 14 days prior to registration; prior treatment with anti-vascular endothelial growth factor (VEGF) targeted agents; AMG 386 therapy; or other molecules that inhibit angiopoietins or TEK tyrosine kinase, endothelial (Tie2) receptor including, but not limited to, XL-820, XL-184 (cabozantinib-s-malate), and CVX-060/PF-4856884 is not allowed regardless of time frame.
  • - Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments.
  • - Treatment within 30 days prior to enrollment with strong immune modulators, including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, lenalidomide, and targeted immune modulators such as abatacept (CTLA-4-Ig), adalimumab, alefacept, anakinra, belatacept (LEA29Y), efalizumab, etanercept, infliximab, or rituximab.
  • - Prior radiotherapy within 90 days (3 months) prior to registration unless there is either: a) histopathologic confirmation of recurrent tumor; or b) new enhancement on MRI outside of the radiation treatment field.
  • - Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 28 days prior to registration or those patients who receive a non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain.
  • - Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib, vandetanib, aflibercept, sunitinib, sorafenib, etc.); prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within 30 days prior to enrollment.
  • - More than 2 relapses.
  • - Therapeutic anticoagulation with warfarin < 7 days prior to registration; (therapeutic or prophylactic therapy with aspirin, a low-molecular weight heparin, or a Factor Xa inhibitor is acceptable) - Intratumoral hemorrhage or peritumoral hemorrhage, demonstrated by MRI or CT scan, CTCAE, v.
4 grade 2 or greater or evidence of significant hemorrhage (regardless of CTCAE, v. 4 grade) defined as > 1 cm diameter of blood (including postoperative hemorrhage)
  • - Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE, v.
4 grade 3 or greater within 30 days prior to study entry.
  • - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within 180 days (6 months) prior to registration.
  • - Transmural myocardial infarction within 180 days (6 months) prior to registration.
  • - History of stroke, cerebral vascular accident (CVA), or transient ischemic attack within 180 days (6 months) prior to registration.
  • - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
  • - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
  • - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
  • - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol.
  • - Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past.
  • - History of non-healing wounds or ulcers, or bone fractures within 90 days (3 months) prior to registration.
  • - History of venous or arterial thromboembolism within 12 months prior to registration.
- Prior allergic reaction to the study drugs involved in this study

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT01609790
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

National Cancer Institute (NCI)
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Eudocia Q Lee
Principal Investigator Affiliation NRG Oncology
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

NIH, Other
Overall Status Completed
Countries Canada, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Additional Details

PRIMARY OBJECTIVES:

  • I. To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1).
(closed to accrual 10/2/12)
  • II. To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).
SECONDARY OBJECTIVES:
  • I. To further assess the toxicity profile (Cohorts 1 and 2).
  • II. To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.
  • III. To determine the radiographic response rate (RR), median progression-free survival (PFS), and overall survival (OS) in bevacizumab-naive patients (Cohort 2).
  • IV. To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).
  • V. To correlate outcome to treatment with tumor genotype, expression profile, and circulating angiogenesis biomarkers in tumor specimens (Cohort 2).
  • VI. To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).
  • VII. To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).
OUTLINE: This is a safety study (cohort 1 [closed to accrual 10/2/12]) followed by a randomized study (cohort 2). Cohort 1: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/2/12) Cohort 2: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive bevacizumab and trebananib as in Cohort 1. ARM II: Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm
  • I. After completion of study treatment, patients are followed up at 30 days, every 2 months for 1 year, every 6 months for 1 year, and then annually thereafter.

Arms & Interventions

Arms

Experimental: Arm I (bevacizumab and trebananib)

Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Active Comparator: Arm II (bevacizumab and placebo)

Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.

Interventions

Biological: - Bevacizumab

Given IV

Other: - Laboratory Biomarker Analysis

Correlative studies

Other: - Pharmacological Study

Correlative studies

Other: - Placebo Administration

Given IV

Biological: - Trebananib

Given IV

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Alaska Breast Care and Surgery LLC, Anchorage, Alaska

Status

Address

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

Alaska Women's Cancer Care, Anchorage, Alaska

Status

Address

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

Anchorage Oncology Centre, Anchorage, Alaska

Status

Address

Anchorage Oncology Centre

Anchorage, Alaska, 99508

Katmai Oncology Group, Anchorage, Alaska

Status

Address

Katmai Oncology Group

Anchorage, Alaska, 99508

Providence Alaska Medical Center, Anchorage, Alaska

Status

Address

Providence Alaska Medical Center

Anchorage, Alaska, 99508

Arizona Oncology-Deer Valley Center, Phoenix, Arizona

Status

Address

Arizona Oncology-Deer Valley Center

Phoenix, Arizona, 85027

Arizona Oncology Services Foundation, Scottsdale, Arizona

Status

Address

Arizona Oncology Services Foundation

Scottsdale, Arizona, 85260

Tucson, Arizona

Status

Address

Arizona Oncology Associates-West Orange Grove

Tucson, Arizona, 85704

Berkeley, California

Status

Address

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704

Mills-Peninsula Medical Center, Burlingame, California

Status

Address

Mills-Peninsula Medical Center

Burlingame, California, 94010

Los Angeles, California

Status

Address

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, 90027

Los Angeles County-USC Medical Center, Los Angeles, California

Status

Address

Los Angeles County-USC Medical Center

Los Angeles, California, 90033

USC / Norris Comprehensive Cancer Center, Los Angeles, California

Status

Address

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Sutter Cancer Research Consortium, Novato, California

Status

Address

Sutter Cancer Research Consortium

Novato, California, 94945

Saint Joseph Hospital - Orange, Orange, California

Status

Address

Saint Joseph Hospital - Orange

Orange, California, 92868

Orange, California

Status

Address

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868

San Francisco, California

Status

Address

California Pacific Medical Center-Pacific Campus

San Francisco, California, 94115

Vallejo, California

Status

Address

Sutter Solano Medical Center/Cancer Center

Vallejo, California, 94589

Poudre Valley Hospital, Fort Collins, Colorado

Status

Address

Poudre Valley Hospital

Fort Collins, Colorado, 80524

Hartford, Connecticut

Status

Address

Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105

The Hospital of Central Connecticut, New Britain, Connecticut

Status

Address

The Hospital of Central Connecticut

New Britain, Connecticut, 06050

Norwich, Connecticut

Status

Address

Eastern Connecticut Hematology and Oncology Associates

Norwich, Connecticut, 06360

William Backus Hospital, Norwich, Connecticut

Status

Address

William Backus Hospital

Norwich, Connecticut, 06360

Broward Health Medical Center, Fort Lauderdale, Florida

Status

Address

Broward Health Medical Center

Fort Lauderdale, Florida, 33316

Piedmont Hospital, Atlanta, Georgia

Status

Address

Piedmont Hospital

Atlanta, Georgia, 30309

Piedmont Fayette Hospital, Fayetteville, Georgia

Status

Address

Piedmont Fayette Hospital

Fayetteville, Georgia, 30214

Gainesville, Georgia

Status

Address

Northeast Georgia Medical Center-Gainesville

Gainesville, Georgia, 30501

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Status

Address

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Rush - Copley Medical Center, Aurora, Illinois

Status

Address

Rush - Copley Medical Center

Aurora, Illinois, 60504

Northwestern University, Chicago, Illinois

Status

Address

Northwestern University

Chicago, Illinois, 60611

Rush University Medical Center, Chicago, Illinois

Status

Address

Rush University Medical Center

Chicago, Illinois, 60612

Chicago, Illinois

Status

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Carle on Vermilion, Danville, Illinois

Status

Address

Carle on Vermilion

Danville, Illinois, 61832

Heartland Cancer Research NCORP, Decatur, Illinois

Status

Address

Heartland Cancer Research NCORP

Decatur, Illinois, 62526

Carle Physician Group-Effingham, Effingham, Illinois

Status

Address

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Evanston, Illinois

Status

Address

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Illinois CancerCare-Galesburg, Galesburg, Illinois

Status

Address

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Glenview, Illinois

Status

Address

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Status

Address

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Good Samaritan Regional Health Center, Mount Vernon, Illinois

Status

Address

Good Samaritan Regional Health Center

Mount Vernon, Illinois, 62864

Carle Cancer Institute Normal, Normal, Illinois

Status

Address

Carle Cancer Institute Normal

Normal, Illinois, 61761

Pekin, Illinois

Status

Address

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center

Pekin, Illinois, 61554

Illinois CancerCare-Peoria, Peoria, Illinois

Status

Address

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Peoria, Illinois

Status

Address

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Peoria, Illinois, 61615

Methodist Medical Center of Illinois, Peoria, Illinois

Status

Address

Methodist Medical Center of Illinois

Peoria, Illinois, 61636

OSF Saint Francis Medical Center, Peoria, Illinois

Status

Address

OSF Saint Francis Medical Center

Peoria, Illinois, 61637

Carle Cancer Center, Urbana, Illinois

Status

Address

Carle Cancer Center

Urbana, Illinois, 61801

The Carle Foundation Hospital, Urbana, Illinois

Status

Address

The Carle Foundation Hospital

Urbana, Illinois, 61801

Warrenville, Illinois

Status

Address

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Rush-Copley Healthcare Center, Yorkville, Illinois

Status

Address

Rush-Copley Healthcare Center

Yorkville, Illinois, 60560

Menorah Medical Center, Overland Park, Kansas

Status

Address

Menorah Medical Center

Overland Park, Kansas, 66209

Saint Luke's South Hospital, Overland Park, Kansas

Status

Address

Saint Luke's South Hospital

Overland Park, Kansas, 66213

Prairie Village, Kansas

Status

Address

Kansas City NCI Community Oncology Research Program

Prairie Village, Kansas, 66208

Lexington, Kentucky

Status

Address

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Maine Medical Center- Scarborough Campus, Scarborough, Maine

Status

Address

Maine Medical Center- Scarborough Campus

Scarborough, Maine, 04074

Ann Arbor, Michigan

Status

Address

Michigan Cancer Research Consortium NCORP

Ann Arbor, Michigan, 48106

Saint Joseph Mercy Hospital, Ann Arbor, Michigan

Status

Address

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, 48106

Beaumont Hospital - Dearborn, Dearborn, Michigan

Status

Address

Beaumont Hospital - Dearborn

Dearborn, Michigan, 48124

Ascension Saint John Hospital, Detroit, Michigan

Status

Address

Ascension Saint John Hospital

Detroit, Michigan, 48236

Green Bay Oncology - Escanaba, Escanaba, Michigan

Status

Address

Green Bay Oncology - Escanaba

Escanaba, Michigan, 49829

Genesys Hurley Cancer Institute, Flint, Michigan

Status

Address

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Hurley Medical Center, Flint, Michigan

Status

Address

Hurley Medical Center

Flint, Michigan, 48503

Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan

Status

Address

Green Bay Oncology - Iron Mountain

Iron Mountain, Michigan, 49801

Bronson Methodist Hospital, Kalamazoo, Michigan

Status

Address

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

West Michigan Cancer Center, Kalamazoo, Michigan

Status

Address

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

Borgess Medical Center, Kalamazoo, Michigan

Status

Address

Borgess Medical Center

Kalamazoo, Michigan, 49048

Sparrow Hospital, Lansing, Michigan

Status

Address

Sparrow Hospital

Lansing, Michigan, 48912

Livonia, Michigan

Status

Address

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Saint Joseph Mercy Oakland, Pontiac, Michigan

Status

Address

Saint Joseph Mercy Oakland

Pontiac, Michigan, 48341

Lake Huron Medical Center, Port Huron, Michigan

Status

Address

Lake Huron Medical Center

Port Huron, Michigan, 48060

William Beaumont Hospital-Royal Oak, Royal Oak, Michigan

Status

Address

William Beaumont Hospital-Royal Oak

Royal Oak, Michigan, 48073

Ascension Saint Mary's Hospital, Saginaw, Michigan

Status

Address

Ascension Saint Mary's Hospital

Saginaw, Michigan, 48601

William Beaumont Hospital - Troy, Troy, Michigan

Status

Address

William Beaumont Hospital - Troy

Troy, Michigan, 48085

Saint John Macomb-Oakland Hospital, Warren, Michigan

Status

Address

Saint John Macomb-Oakland Hospital

Warren, Michigan, 48093

Fairview Ridges Hospital, Burnsville, Minnesota

Status

Address

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

Mercy Hospital, Coon Rapids, Minnesota

Status

Address

Mercy Hospital

Coon Rapids, Minnesota, 55433

Fairview Southdale Hospital, Edina, Minnesota

Status

Address

Fairview Southdale Hospital

Edina, Minnesota, 55435

Unity Hospital, Fridley, Minnesota

Status

Address

Unity Hospital

Fridley, Minnesota, 55432

Hutchinson Area Health Care, Hutchinson, Minnesota

Status

Address

Hutchinson Area Health Care

Hutchinson, Minnesota, 55350

Maplewood, Minnesota

Status

Address

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Saint John's Hospital - Healtheast, Maplewood, Minnesota

Status

Address

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Abbott-Northwestern Hospital, Minneapolis, Minnesota

Status

Address

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Hennepin County Medical Center, Minneapolis, Minnesota

Status

Address

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Health Partners Inc, Minneapolis, Minnesota

Status

Address

Health Partners Inc

Minneapolis, Minnesota, 55454

North Memorial Medical Health Center, Robbinsdale, Minnesota

Status

Address

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Saint Louis Park, Minnesota

Status

Address

Metro Minnesota Community Oncology Research Consortium

Saint Louis Park, Minnesota, 55416

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

Status

Address

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Regions Hospital, Saint Paul, Minnesota

Status

Address

Regions Hospital

Saint Paul, Minnesota, 55101

United Hospital, Saint Paul, Minnesota

Status

Address

United Hospital

Saint Paul, Minnesota, 55102

Saint Francis Regional Medical Center, Shakopee, Minnesota

Status

Address

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

Ridgeview Medical Center, Waconia, Minnesota

Status

Address

Ridgeview Medical Center

Waconia, Minnesota, 55387

Rice Memorial Hospital, Willmar, Minnesota

Status

Address

Rice Memorial Hospital

Willmar, Minnesota, 56201

Woodbury, Minnesota

Status

Address

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

University of Mississippi Medical Center, Jackson, Mississippi

Status

Address

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Singing River Hospital, Pascagoula, Mississippi

Status

Address

Singing River Hospital

Pascagoula, Mississippi, 39581

Saint Francis Medical Center, Cape Girardeau, Missouri

Status

Address

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Centerpoint Medical Center LLC, Independence, Missouri

Status

Address

Centerpoint Medical Center LLC

Independence, Missouri, 64057

Freeman Health System, Joplin, Missouri

Status

Address

Freeman Health System

Joplin, Missouri, 64804

Mercy Hospital Joplin, Joplin, Missouri

Status

Address

Mercy Hospital Joplin

Joplin, Missouri, 64804

Saint Luke's Hospital of Kansas City, Kansas City, Missouri

Status

Address

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, 64111

North Kansas City Hospital, Kansas City, Missouri

Status

Address

North Kansas City Hospital

Kansas City, Missouri, 64116

Kansas City, Missouri

Status

Address

Heartland Hematology and Oncology Associates Incorporated

Kansas City, Missouri, 64118

Research Medical Center, Kansas City, Missouri

Status

Address

Research Medical Center

Kansas City, Missouri, 64132

Saint Luke's East - Lee's Summit, Lee's Summit, Missouri

Status

Address

Saint Luke's East - Lee's Summit

Lee's Summit, Missouri, 64086

Liberty Radiation Oncology Center, Liberty, Missouri

Status

Address

Liberty Radiation Oncology Center

Liberty, Missouri, 64068

Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri

Status

Address

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

Heartland Regional Medical Center, Saint Joseph, Missouri

Status

Address

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

Saint Joseph Oncology Inc, Saint Joseph, Missouri

Status

Address

Saint Joseph Oncology Inc

Saint Joseph, Missouri, 64507

Saint Louis, Missouri

Status

Address

Saint Louis Cancer and Breast Institute-South City

Saint Louis, Missouri, 63109

Mercy Hospital Saint Louis, Saint Louis, Missouri

Status

Address

Mercy Hospital Saint Louis

Saint Louis, Missouri, 63141

Cancer Research for the Ozarks NCORP, Springfield, Missouri

Status

Address

Cancer Research for the Ozarks NCORP

Springfield, Missouri, 65804

Mercy Hospital Springfield, Springfield, Missouri

Status

Address

Mercy Hospital Springfield

Springfield, Missouri, 65804

CoxHealth South Hospital, Springfield, Missouri

Status

Address

CoxHealth South Hospital

Springfield, Missouri, 65807

Nebraska Methodist Hospital, Omaha, Nebraska

Status

Address

Nebraska Methodist Hospital

Omaha, Nebraska, 68114

New York Oncology Hematology PC - Albany, Albany, New York

Status

Address

New York Oncology Hematology PC - Albany

Albany, New York, 12206

Albany, New York

Status

Address

New York Oncology Hematology PC - Albany Medical Center

Albany, New York, 12208

Auburn, New York

Status

Address

Hematology Oncology Associates of Central New York-Auburn

Auburn, New York, 13021

Montefiore Medical Center - Moses Campus, Bronx, New York

Status

Address

Montefiore Medical Center - Moses Campus

Bronx, New York, 10467

East Syracuse, New York

Status

Address

Hematology Oncology Associates of Central New York-East Syracuse

East Syracuse, New York, 13057

Liverpool, New York

Status

Address

Hematology Oncology Associates of Central New York-Liverpool

Liverpool, New York, 13088

New York, New York

Status

Address

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016

New York, New York

Status

Address

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032

Rome, New York

Status

Address

Hematology Oncology Associates of Central New York-Rome

Rome, New York, 13440

Syracuse, New York

Status

Address

Hematology Oncology Associates of Central New York-Onondaga Hill

Syracuse, New York, 13215

Mission Hospital, Asheville, North Carolina

Status

Address

Mission Hospital

Asheville, North Carolina, 28801

Mountain Radiation Oncology PA, Asheville, North Carolina

Status

Address

Mountain Radiation Oncology PA

Asheville, North Carolina, 28801

AdventHealth Infusion Center Asheville, Asheville, North Carolina

Status

Address

AdventHealth Infusion Center Asheville

Asheville, North Carolina, 28803

Messino Cancer Centers, Asheville, North Carolina

Status

Address

Messino Cancer Centers

Asheville, North Carolina, 28806

AdventHealth Hendersonville, Hendersonville, North Carolina

Status

Address

AdventHealth Hendersonville

Hendersonville, North Carolina, 28792

Rutherford Hospital, Rutherfordton, North Carolina

Status

Address

Rutherford Hospital

Rutherfordton, North Carolina, 28139

Winston-Salem, North Carolina

Status

Address

Southeast Clinical Oncology Research Consortium NCORP

Winston-Salem, North Carolina, 27104

Summa Health System - Akron Campus, Akron, Ohio

Status

Address

Summa Health System - Akron Campus

Akron, Ohio, 44304

Cleveland Clinic Akron General, Akron, Ohio

Status

Address

Cleveland Clinic Akron General

Akron, Ohio, 44307

Summa Health System - Barberton Campus, Barberton, Ohio

Status

Address

Summa Health System - Barberton Campus

Barberton, Ohio, 44203

Strecker Cancer Center-Belpre, Belpre, Ohio

Status

Address

Strecker Cancer Center-Belpre

Belpre, Ohio, 45714

Adena Regional Medical Center, Chillicothe, Ohio

Status

Address

Adena Regional Medical Center

Chillicothe, Ohio, 45601

Cincinnati, Ohio

Status

Address

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Columbus, Ohio

Status

Address

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214

Riverside Methodist Hospital, Columbus, Ohio

Status

Address

Riverside Methodist Hospital

Columbus, Ohio, 43214

Columbus, Ohio

Status

Address

Columbus NCI Community Oncology Research Program

Columbus, Ohio, 43215

Grant Medical Center, Columbus, Ohio

Status

Address

Grant Medical Center

Columbus, Ohio, 43215

The Mark H Zangmeister Center, Columbus, Ohio

Status

Address

The Mark H Zangmeister Center

Columbus, Ohio, 43219

Mount Carmel Health Center West, Columbus, Ohio

Status

Address

Mount Carmel Health Center West

Columbus, Ohio, 43222

Doctors Hospital, Columbus, Ohio

Status

Address

Doctors Hospital

Columbus, Ohio, 43228

Delaware, Ohio

Status

Address

Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015

Delaware Radiation Oncology, Delaware, Ohio

Status

Address

Delaware Radiation Oncology

Delaware, Ohio, 43015

Grady Memorial Hospital, Delaware, Ohio

Status

Address

Grady Memorial Hospital

Delaware, Ohio, 43015

Fairfield Medical Center, Lancaster, Ohio

Status

Address

Fairfield Medical Center

Lancaster, Ohio, 43130

Lancaster Radiation Oncology, Lancaster, Ohio

Status

Address

Lancaster Radiation Oncology

Lancaster, Ohio, 43130

Marietta Memorial Hospital, Marietta, Ohio

Status

Address

Marietta Memorial Hospital

Marietta, Ohio, 45750

Summa Health Medina Medical Center, Medina, Ohio

Status

Address

Summa Health Medina Medical Center

Medina, Ohio, 44256

Knox Community Hospital, Mount Vernon, Ohio

Status

Address

Knox Community Hospital

Mount Vernon, Ohio, 43050

Licking Memorial Hospital, Newark, Ohio

Status

Address

Licking Memorial Hospital

Newark, Ohio, 43055

Newark Radiation Oncology, Newark, Ohio

Status

Address

Newark Radiation Oncology

Newark, Ohio, 43055

Southern Ohio Medical Center, Portsmouth, Ohio

Status

Address

Southern Ohio Medical Center

Portsmouth, Ohio, 45662

Ravenna, Ohio

Status

Address

University Hospitals Portage Medical Center

Ravenna, Ohio, 44266

Springfield Regional Medical Center, Springfield, Ohio

Status

Address

Springfield Regional Medical Center

Springfield, Ohio, 45505

West Chester, Ohio

Status

Address

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Saint Ann's Hospital, Westerville, Ohio

Status

Address

Saint Ann's Hospital

Westerville, Ohio, 43081

Zanesville, Ohio

Status

Address

Genesis Healthcare System Cancer Care Center

Zanesville, Ohio, 43701

Oklahoma City, Oklahoma

Status

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Tulsa, Oklahoma

Status

Address

Natalie Warren Bryant Cancer Center at Saint Francis

Tulsa, Oklahoma, 74136

Tulsa, Oklahoma

Status

Address

Oklahoma Cancer Specialists and Research Institute-Tulsa

Tulsa, Oklahoma, 74146

Warren Clinic Oncology-Tulsa, Tulsa, Oklahoma

Status

Address

Warren Clinic Oncology-Tulsa

Tulsa, Oklahoma, 74146

Clackamas Radiation Oncology Center, Clackamas, Oregon

Status

Address

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

Willamette Valley Cancer Center, Eugene, Oregon

Status

Address

Willamette Valley Cancer Center

Eugene, Oregon, 97401

Providence Portland Medical Center, Portland, Oregon

Status

Address

Providence Portland Medical Center

Portland, Oregon, 97213

Providence Saint Vincent Medical Center, Portland, Oregon

Status

Address

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Beaver, Pennsylvania

Status

Address

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009

Bethlehem, Pennsylvania

Status

Address

Saint Luke's University Hospital-Bethlehem Campus

Bethlehem, Pennsylvania, 18015

Bryn Mawr Hospital, Bryn Mawr, Pennsylvania

Status

Address

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, 19010

UPMC Cancer Center at UPMC Horizon, Farrell, Pennsylvania

Status

Address

UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121

Adams Cancer Center, Gettysburg, Pennsylvania

Status

Address

Adams Cancer Center

Gettysburg, Pennsylvania, 17325

Greensburg, Pennsylvania

Status

Address

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Cherry Tree Cancer Center, Hanover, Pennsylvania

Status

Address

Cherry Tree Cancer Center

Hanover, Pennsylvania, 17331

Johnstown, Pennsylvania

Status

Address

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, 15901

Lancaster General Hospital, Lancaster, Pennsylvania

Status

Address

Lancaster General Hospital

Lancaster, Pennsylvania, 17602

UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania

Status

Address

UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, 15132

UPMC Cancer Center-Natrona Heights, Natrona Heights, Pennsylvania

Status

Address

UPMC Cancer Center-Natrona Heights

Natrona Heights, Pennsylvania, 15065

UPMC Jameson, New Castle, Pennsylvania

Status

Address

UPMC Jameson

New Castle, Pennsylvania, 16105

Paoli Memorial Hospital, Paoli, Pennsylvania

Status

Address

Paoli Memorial Hospital

Paoli, Pennsylvania, 19301

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Status

Address

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania

Status

Address

UPMC-Presbyterian Hospital

Pittsburgh, Pennsylvania, 15213

UPMC-Saint Margaret, Pittsburgh, Pennsylvania

Status

Address

UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215

UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania

Status

Address

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Pittsburgh, Pennsylvania

Status

Address

UPMC Jefferson Regional Radiation Oncology

Pittsburgh, Pennsylvania, 15236

UPMC-Passavant Hospital, Pittsburgh, Pennsylvania

Status

Address

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania

Status

Address

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243

UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania

Status

Address

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346

Uniontown, Pennsylvania

Status

Address

UPMC Uniontown Hospital Radiation Oncology

Uniontown, Pennsylvania, 15401

Washington, Pennsylvania

Status

Address

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301

Reading Hospital, West Reading, Pennsylvania

Status

Address

Reading Hospital

West Reading, Pennsylvania, 19611

Lankenau Medical Center, Wynnewood, Pennsylvania

Status

Address

Lankenau Medical Center

Wynnewood, Pennsylvania, 19096

Main Line Health NCORP, Wynnewood, Pennsylvania

Status

Address

Main Line Health NCORP

Wynnewood, Pennsylvania, 19096

WellSpan Health-York Hospital, York, Pennsylvania

Status

Address

WellSpan Health-York Hospital

York, Pennsylvania, 17403

AnMed Health Cancer Center, Anderson, South Carolina

Status

Address

AnMed Health Cancer Center

Anderson, South Carolina, 29621

Gibbs Cancer Center-Pelham, Greer, South Carolina

Status

Address

Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651

Spartanburg Medical Center, Spartanburg, South Carolina

Status

Address

Spartanburg Medical Center

Spartanburg, South Carolina, 29303

Rapid City Regional Hospital, Rapid City, South Dakota

Status

Address

Rapid City Regional Hospital

Rapid City, South Dakota, 57701

Texas Oncology-Austin Midtown, Austin, Texas

Status

Address

Texas Oncology-Austin Midtown

Austin, Texas, 78705

Austin, Texas

Status

Address

Texas Oncology - Central Austin Cancer Center

Austin, Texas, 78731

Austin, Texas

Status

Address

Texas Oncology - South Austin Cancer Center

Austin, Texas, 78745

Texas Oncology Bedford, Bedford, Texas

Status

Address

Texas Oncology Bedford

Bedford, Texas, 76022

Dallas, Texas

Status

Address

Texas Oncology at Baylor Charles A Sammons Cancer Center

Dallas, Texas, 75246

Dallas, Texas

Status

Address

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Fort Worth, Texas

Status

Address

Texas Oncology - Fort Worth Cancer Center

Fort Worth, Texas, 76104

Texas Oncology-Grapevine, Grapevine, Texas

Status

Address

Texas Oncology-Grapevine

Grapevine, Texas, 76053

Texas Oncology-Longview Cancer Center, Longview, Texas

Status

Address

Texas Oncology-Longview Cancer Center

Longview, Texas, 75601

Texas Oncology-Seton Williamson, Round Rock, Texas

Status

Address

Texas Oncology-Seton Williamson

Round Rock, Texas, 78665

Round Rock, Texas

Status

Address

Texas Oncology - Round Rock Cancer Center

Round Rock, Texas, 78681

Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas

Status

Address

Texas Oncology Cancer Center Sugar Land

Sugar Land, Texas, 77479

Tyler Cancer Center, Tyler, Texas

Status

Address

Tyler Cancer Center

Tyler, Texas, 75702

American Fork, Utah

Status

Address

American Fork Hospital / Huntsman Intermountain Cancer Center

American Fork, Utah, 84003

Sandra L Maxwell Cancer Center, Cedar City, Utah

Status

Address

Sandra L Maxwell Cancer Center

Cedar City, Utah, 84720

Logan Regional Hospital, Logan, Utah

Status

Address

Logan Regional Hospital

Logan, Utah, 84321

Intermountain Medical Center, Murray, Utah

Status

Address

Intermountain Medical Center

Murray, Utah, 84107

McKay-Dee Hospital Center, Ogden, Utah

Status

Address

McKay-Dee Hospital Center

Ogden, Utah, 84403

Utah Valley Regional Medical Center, Provo, Utah

Status

Address

Utah Valley Regional Medical Center

Provo, Utah, 84604

Saint George Regional Medical Center, Saint George, Utah

Status

Address

Saint George Regional Medical Center

Saint George, Utah, 84770

Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah

Status

Address

Utah Cancer Specialists-Salt Lake City

Salt Lake City, Utah, 84106

LDS Hospital, Salt Lake City, Utah

Status

Address

LDS Hospital

Salt Lake City, Utah, 84143

Cancer Care Northwest - Spokane South, Spokane, Washington

Status

Address

Cancer Care Northwest - Spokane South

Spokane, Washington, 99202

Cancer Care Northwest-North Spokane, Spokane, Washington

Status

Address

Cancer Care Northwest-North Spokane

Spokane, Washington, 99218

PeaceHealth Southwest Medical Center, Vancouver, Washington

Status

Address

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

Compass Oncology Vancouver, Vancouver, Washington

Status

Address

Compass Oncology Vancouver

Vancouver, Washington, 98684

Langlade Hospital and Cancer Center, Antigo, Wisconsin

Status

Address

Langlade Hospital and Cancer Center

Antigo, Wisconsin, 54409

Green Bay, Wisconsin

Status

Address

Green Bay Oncology at Saint Vincent Hospital

Green Bay, Wisconsin, 54301-3526

Green Bay, Wisconsin

Status

Address

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Green Bay, Wisconsin

Status

Address

Green Bay Oncology Limited at Saint Mary's Hospital

Green Bay, Wisconsin, 54303

Green Bay, Wisconsin

Status

Address

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Madison, Wisconsin

Status

Address

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792

Holy Family Memorial Hospital, Manitowoc, Wisconsin

Status

Address

Holy Family Memorial Hospital

Manitowoc, Wisconsin, 54221

Bay Area Medical Center, Marinette, Wisconsin

Status

Address

Bay Area Medical Center

Marinette, Wisconsin, 54143

Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin

Status

Address

Froedtert Menomonee Falls Hospital

Menomonee Falls, Wisconsin, 53051

Medical College of Wisconsin, Milwaukee, Wisconsin

Status

Address

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

ProHealth D N Greenwald Center, Mukwonago, Wisconsin

Status

Address

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Cancer Center of Western Wisconsin, New Richmond, Wisconsin

Status

Address

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin

Status

Address

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Oconto Falls, Wisconsin

Status

Address

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Sturgeon Bay, Wisconsin

Status

Address

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin

Status

Address

Green Bay Oncology - Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235

ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin

Status

Address

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188

Aspirus Regional Cancer Center, Wausau, Wisconsin

Status

Address

Aspirus Regional Cancer Center

Wausau, Wisconsin, 54401

International Sites

Allan Blair Cancer Centre, Regina, Saskatchewan, Canada

Status

Address

Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1